The Impact of Sarilumab on Patient Reported Outcomes

EP: 1.Updates to Polymyalgia Rheumatica Care: Sarilumab Insights

EP: 2.SAPHYR Trial: Sarilumab’s Impact on Refractory Polymyalgia Rheumatica

EP: 3.Key Patient Characteristics in the SAPHYR Trial

Now Viewing

EP: 4.The Impact of Sarilumab on Patient Reported Outcomes

EP: 5.Polymyalgia Rheumatica: Achieving Sustained Remission

EP: 6.Updating Guidelines and Payer Access for Refractory Polymyalgia Rheumatica

EP: 7.SAPHYR Study Insights and Limitations

EP: 8.How the SAPHYR Trial Has Impacted Rheumatology Care

This is a video synopsis/summary of a Between the Lines involving Robert Spiera, M.D., and Dana McCormick, R.Ph.

In this insightful discussion between Dana McCormick, R.Ph., and Robert Spiera, M.D., the focus was on analyzing outcomes and their implications for future patient treatments. Spiera emphasized the importance of various outcome features in treating vulnerable populations. Notably, achieving remission by week 12 and reducing steroid use throughout the year, especially in patients who had prior steroid exposure, stood out as a clinically significant outcome. The discussion highlighted the interplay of different outcomes, with patient-reported outcomes favoring treatment with sarilumab.

Spiera elaborated on the positive impact seen in patient-reported outcomes, encompassing improvements in fatigue scores and quality-of-life assessments. The SF-36, measuring both physical and mental components, demonstrated statistically significant benefits from sarilumab treatment. The totality of the data, including reduced steroid usage and improved patient-reported outcomes, contributed to the excitement expressed by Spiera, anticipating FDA approval. The discussion underscores the multifaceted approach to assessing therapies, considering how patients feel, function and survive, with sarilumab demonstrating positive impacts across various domains.

This summary was AI-generated and reviewed by Managed Healthcare Executive^® staff.